Theorem Clinical Research continues to broaden its ability to help sponsors optimize trial conduct
Theorem Clinical Research
continues to broaden its ability to help sponsors optimize trial conduct, recently implementing SAS® Clinical Data Integration (SAS CDI), an innovative solution that automates the process of transforming, managing and verifying the creation of industry-mandated data standards.
SAS enables Theorem to automate the mapping of standard electronic data capture (EDC) databases and external data into standard data sets that are compliant with the Clinical Data Interchange Standards Consortium (CDISC). By using the technology for routine tasks, Theorem can now more easily manage standards throughout the entire life cycle.
Additionally, SAS CDI will be leveraged to automate Theorem’s clinical data warehouse and highly visual data discovery tools, reducing time and effort to obtain clinical data in real time.
“As an early supporter of CDISC, Theorem recognized the value that standardization and harmonization would bring to clinical data and reporting,” said Mark Penniston, executive vice president of clinical analytics for Theorem. “Now we’re able to combine our deep experience in developing CDISC-compliant data domains with SAS technology to produce high-quality, standardized data sets faster and more efficiently.”
Kecia Serwin, vice president,
SAS Health Care and Life Sciences
, commented, “We’re delighted that Theorem has joined the list of leading life science organizations who’ve chosen SAS to streamline standards adoption in drug development processes.”
As a
CDISC Registered Solutions Provider,
Theorem was among the first global contract research organizations to execute a CDISC-compliant submission in 2004 and has created more than 50,000 CDISC-compliant data sets to date.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.